Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430843 · ClinicalTrials.gov registry record · Phase 3
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
A Phase 3 study of Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene.
- Completed
- Registry status
- Phase 3
- Development phase
- 512
- Enrollment target
- 20
- Study locations
NCT03430843: Completed Phase 3 study of Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene.
NCT03430843 is a Phase 3 study of Esophageal Squamous Cell Carcinoma (ESCC) that has completed, run by BeiGene. The registered enrollment target is 512 participants, roughly in line with the 517-participant average among 5 other Esophageal Squamous Cell Carcinoma (ESCC) trials with a reported enrollment target. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03430843, a Phase 3 study of Esophageal Squamous Cell Carcinoma (ESCC), has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 512 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
Primary Outcome
OS is defined as the length of time from the date of randomization until the date of death due to any cause in all randomized participants
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Tislelizumab
- DRUG Paclitaxel
- DRUG Irinotecan
Study Locations (20)
Other
- Imelda Ziekenhuis Bonheiden - Bonheiden
- Cliniques Universitaires Saint Luc - Brussels
- Uz Antwerpen - Edegem
- University Hospitals Leuven - Leuven
Fujian
- Fujian Medical University Union Hospital - Fuzhou
- The First Affiliated Hospital of Fujian Medical University - Fuzhou
- Fujian Cancer Hospital - Fuzhou
- The First Affiliated Hospital of Xiamen University - Xiamen
Guangdong
- The First Affiliated Hospital, Sun Yat Sen University - Guangzhou
- The Sixth Affiliated Hospital, Sun Yat Sen University - Guangzhou
- Cancer Hospital of Shantou University Medical College - Shantou
- Peking University Shenzhen Hospital - Shenzhen
Beijing Municipality
- Beijing Friendship Hospital, Capital Medical University - Beijing
- Beijing Cancer Hospital - Beijing
- Peking Union Medical College Hospital - Beijing
Michigan
- Henry Ford Hospital - Detroit
Ohio
- Toledo Clinic Cancer Center - Toledo
Anhui
- The Second Hospital of Anhui Medical University - Hefei
Hebei
- Affiliated Hospital of Hebei University - Baoding
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2022-12-28 |
| Phase | Phase 3 |
What the finished NCT03430843 record still lists
NCT03430843 is an interventional study that assigns participants to a tested intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 517-participant average among 5 other Esophageal Squamous Cell Carcinoma (ESCC) trials with a reported enrollment target.
The record links to 1 condition, with Esophageal Squamous Cell Carcinoma (ESCC) appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT03430843 names 20 study sites across 9 states, led by Other, Fujian, Guangdong.
Frequently Asked Questions
What is clinical trial NCT03430843 about?
NCT03430843 is a clinical study titled "A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma". The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
What is the current status of trial NCT03430843?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 512 participants. The study started on 2018-01-26. Estimated completion is 2022-12-28.
What conditions does trial NCT03430843 study?
This clinical trial studies the following conditions: Esophageal Squamous Cell Carcinoma (ESCC).
What interventions are being tested in trial NCT03430843?
The interventions under investigation include: Docetaxel (DRUG), Tislelizumab (DRUG), Paclitaxel (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT03430843?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03430843 being conducted?
This trial has 20 study locations across Michigan, Ohio, Anhui, Beijing Municipality, Fujian. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Squamous Cell Carcinoma (ESCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
COMPLETED · Phase 3
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
RECRUITING
-
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI